As part of a plan to establish a network of manufacturing partners to help boost capacity ahead of a potential FDA approval of a Covid-19 vaccine, US healthcare giant...
17.08.2018
- US specialty biopharma Emergent BioSolutions has agreed to buy PaxVax in an all-cash deal worth $270 million. PaxVax is majority owned by an affiliate of American private equity...
